Table 1 Baseline clinical characteristics of patients.
Overall (n = 587) | Users of RAS inhibitor (n = 94) | Non-users of RAS inhibitor (n = 493) | P value | |
|---|---|---|---|---|
Demographic characteristics | ||||
Age, years | 61.8 (14.8) | 60.9 (12.3) | 62.0 (15.2) | 0.45 |
Man, N (%) | 406 (69.2%) | 69 (73.4%) | 337 (68.4%) | 0.33 |
Diabetes mellitus, N (%) | 184 (31.4%) | 31 (33.0%) | 153 (31.0%) | 0.71 |
Hypertension, N (%) | 317 (54.0%) | 88 (93.6%) | 229 (46.5%) | < 0.001 |
Congestive heart failure NYHA III or IV, N (%) | 191 (32.5%) | 21 (22.3%) | 170 (34.5%) | 0.02 |
Coronary artery disease, N (%) | 366 (62.4%) | 66 (70.2%) | 300 (60.9%) | 0.09 |
Peripheral arterial occlusive disease, N (%) | 54 (9.2%) | 10 (10.6%) | 44 (8.9%) | 0.60 |
Hyperlipidemia, N (%) | 163 (27.8%) | 28 (29.8%) | 135 (27.4%) | 0.63 |
Chronic obstructive pulmonary disease, N (%) | 70 (11.9%) | 11 (11.7%) | 59 (12.0%) | 0.94 |
Chronic hepatitis, N (%) | 16 (2.7%) | 1 (1.1%) | 15 (3.0%) | 0.28 |
Hyperuricemia, N (%) | 81 (13.8%) | 10 (10.6%) | 71 (14.4%) | 0.33 |
Metastatic cancer, N (%) | 140 (23.9%) | 19 (20.2%) | 121 (24.5%) | 0.37 |
Current or former smoker, N (%) | 50 (8.5%) | 11 (11.7%) | 39 (7.9%) | 0.23 |
Laboratory data | ||||
Baseline hemoglobin, g/dl (SD) | 13.2 (1.8) | 13.5 (1.6) | 13.2 (1.8) | 0.09 |
Baseline albumin, g/dl (SD) | 4.2 (0.5) | 4.3 (0.5) | 4.2 (0.5) | 0.55 |
Baseline SCr, mg/dl (SD) | 0.85 (0.18) | 0.87 (0.16) | 0.85 (0.19) | 0.28 |
Baseline eGFR, ml/min/1.73 m2 (SD) | 89.0 (25.2) | 86.3 (18.4) | 89.5 (26.3) | 0.15 |
SCr at AKI, mg/dl (SD) | 1.65 (1.01) | 1.61 (0.85) | 1.66 (1.04) | 0.60 |
SCr at AKI recovery, mg/dl (SD) | 0.91 (0.06) | 0.94 (0.17) | 0.91 (0.08) | 0.14 |
Urine protein at AKI (severe), N (%) | 28 (4.8%) | 7 (7.5%) | 21 (4.3%) | 0.18 |
AKI stage, N (%) | ||||
Stage I | 539 (91.8%) | 89 (94.7%) | 450 (91.3%) | 0.37 |
Stage II + Stage III | 48 (8.2%) | 5 (5.3%) | 43 (8.7%) | 0.37 |
Surgical procedure, N (%) | ||||
Coronary artery bypass grafting | 232 (39.5%) | 38 (40.4%) | 194 (39.4%) | 0.94 |
Valve surgery | 217 (37.0%) | 28 (29.8%) | 189 (38.3%) | 0.15 |
Heart transplant | 37 (6.3%) | 2 (2.1%) | 35 (7.1%) | 0.11 |
Other cardiac surgery | 101 (17.2%) | 26 (27.7%) | 75 (15.2%) | 0.005 |
Medication at discharge, N (%) | ||||
Anti-HTN agents | 214 (36.5%) | 82 (87.2%) | 132 (26.8%) | <0.001 |
Statins | 149 (25.4%) | 28 (29.8%) | 121 (24.5%) | 0.28 |
Immunosuppressants | 37 (6.3%) | 2 (2.1%) | 35 (7.1%) | 0.07 |
